CD274 and neoplasm: A promising therapeutic approach is to combine a PD-1/PD-L1 ICI with chemotherapy, EGFR TKI, or other type of ICI with an aim to increase the immunogenicity of tumor cells, or to inhibit immunosuppressive signaling in the TME (111).